Clinical correlates and drug treatment of residents with stroke in long-term care

Stroke

Volumn 32, Issue 6, 2001, Pages 1385-1392

  Quilliam, Brian J ^a   Lapane, Kate L ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Anticoagulants; Cerebrovascular accident; Nursing homes; Platelet aggregation inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; DIPYRIDAMOLE; TICLOPIDINE; WARFARIN;

AGED; ALZHEIMER DISEASE; ARTICLE; COGNITIVE DEFECT; COMORBIDITY; DEMENTIA; DEPRESSION; ETHNIC DIFFERENCE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERTENSION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NURSING HOME; PEPTIC ULCER; PRIORITY JOURNAL; STROKE;

EID: 0034983277     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.str.32.6.1385     Document Type: Article

References (66)

1. Deaths. Final data for 1998
2. Lifetime cost of stroke in the United States
3. The Lausanne stroke registry: Analysis of 1000 consecutive patients with first stroke
4. The incidence of stroke in the Kuopio area of East Finland
5. The national survey of stroke: Survival and prevalence
6. National hospital discharge survey: Annual summary, 1998: National Center for Health Statistics
7. Poststroke rehabilitation in older Americans: The medicare experience
8. Stroke-attributable nursing home use: A population-based study
9. A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE)
10. European stroke prevention study, II: Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke
11. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamole alone and in combination
12. The Canadian American ticlopidine study (CATS) in thromboembolic stroke
13. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg of aspirin as secondary prophylaxis after cerebrovascular ischemic events
14. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke
15. Frequency of major complications of aspirin, warfarin, and intravenous heparin for secondary stroke prevention
16. The SAGE database: Introducing functional outcomes in geriatric pharmaco-epidemiology
17. Characteristics of the SAGE database: A new resource for research on outcomes in long-term care: SAGE (Systematic Assessment of Geriatric drug use via Epidemiology) Study Group
18. The SAGE database: Medication use in elderly nursing facility residents
19. Designing the national resident assessment instrument for nursing homes
20. Reliability estimates for the minimum data set for nursing home resident assessment and care screening (MDS)
21. The MDS cognition scale: A valid instrument for identifying and staging nursing home residents with dementia using the minimum data set
22. Validation of the minimum data set cognitive performance scale: Agreement with the mini-mental state examination
23. MDS cognitive performance scale
24. Inaccuracy of the international classification of diseases (ICD-9-CM) in identifying the diagnosis of ischemic cerebrovascular disease
25. Accuracy of ICD-9-CM coding for the identification of patients with acute ischemic stroke: Effect of modifier codes
26. Accuracy of hospital discharge abstracts for identifying stroke
27. Validity of diagnostic and drug data in standardized nursing home resident assessments: Potential for geriatric pharmacoepidemiology: SAGE Study Group: Systematic Assessment of Geriatric drug use via Epidemiology
28. Survival and recurrence after first cerebral infarction: A population-based study in Rochester, Minnesota, 1975 through 1989
29. Hypertension and risk of stroke recurrence
30. The J-curve phenomenon in stroke recurrence
31. A multifactorial analysis of risk factors for recurrence of ischemic stroke
32. Beneficial effects of carotid endarterectomy in symptomatic patients with high grade carotid stenosis
33. Survival and recurrence following stroke: The Framingham study
34. Dementia after stroke increases the risk of long-term stroke recurrence
35. Stroke in the Lehigh Valley: Risk factors for recurrent stroke
36. Stroke recurrence: Predictors, severity, and prognosis. The Copenhagen stroke study
37. Cost-effectiveness of warfarin and aspirin for propylaxis of stroke in patients with nonvalvular atrial fibrillation
38. Stroke prevention: Windows of opportunity and failed expectations? A discussion of modifiable cardiovascular risk factors and a prevention proposal
39. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: A statement for healthcare professionals from the stroke council of the American heart association
40. Use of antithrombotic measures for stroke prevention in atrial fibrillation
41. Antithrombotic therapy for stroke prevention among medicare beneficiaries hospitalized in Alaska with atrial fibrillation
42. Atrial fibrillation and anticoagulation in patients with permanent pacemakers: Implications for stroke prevention
43. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study
44. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation: Veterans affairs stroke prevention in nonrheumatic atrial fibrillation investigators
45. Design of a multicenter randomized trial for the stroke prevention in atrial fibrillation study: The stroke prevention in atrial fibrillation investigators
46. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston area anticoagulation trial for atrial fibrillation investigators
47. Stroke prevention in atrial fibrillation study. Final results
48. Physicians' attitudes toward oral anticoagulants and antiplatelet agents for stroke prevention in elderly patients with atrial fibrillation
49. Physician attitudes concerning warfarin for stroke prevention in atrial fibrillation: Results of a survey of long-term care practitioners
50. Atrial fibrillation and stroke prevention with warfarin in the long-term care setting
51. Comparison of an anticoagulation clinic with usual medical care: Anticoagulation control, patient outcomes, and health care costs
52. Efficient operation of a high-volume anticoagulation clinic
53. Effect of a pharmacist-managed anticoagulation clinic on warfarin-related hospital readmissions
54. Risk factors for rebleeding and death from peptic ulcer in the very elderly
55. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors: Stroke prevention in reversible ischemia trial (SPIRIT): European atrial fibrillation trial (EAFT) study groups
56. Black-white differences in stroke frequency: Challenges for research
57. Prevalence, clinical correlates, and treatment of hypertension in elderly nursing home residents: SAGE (Systematic Assessment of Geriatric Drug Use via Epidemiology) Study Group
58. Prevalence, clinical characteristics, and pharmacologic treatment of Parkinson's disease in residents in long-term care facilities: SAGE Study Group
59. Correlates and management of nonmalignant pain in the nursing home: SAGE Study Group: Systematic Assessment of Geriatric drug use via Epidemiology
60. Stroke in the Lehigh Valley: Racial/ethnic differences
61. Stroke incidence among white, black, and Hispanic residents of an urban community: The Northern Manhattan stroke study
62. Stroke incidence and survival among middle-aged adults: 9-year follow-up of the atherosclerosis risk in communities (ARIC) cohort
63. Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infarcts, lacunes and transient ischaemic attacks: The stroke registry of Dijon: 1985-1989
64. Trends in validated cases of fatal and non-fatal stroke, stroke classification, and risk factors in Southeastern New England, 1980 to 1991